Dipharma Francis S.r.l.

Dipharma Sa

Emanuele Attolino

Pietro Allegrini

Gabriele Razzetti

Renzo Graziosi

Andrea Malvestiti

Vittorio Lucchini

Alessandro Lombardo

Luca Giannotti

Simone Mantegazza

Alessandro Restelli

Chiara Vladiskovic

Marco Artico

Davide Rossi

Mario Michieletti

Lino Colombo

Enrico Brunoldi

Ilaria Mormino

Gianmaria Dell'Anna

Niccolo Santillo

Simone Tambini

Mauro Mittino

Davide Brenna

Niccolo′ Santillo

Grazia Iannucci

Anna Iuliano

Gianmaria Dell'anna

Niccolò Santillo

Pietro Allergrini

The present invention relates to a process for the preparation of migalastat of formula (I) and intermediates useful in the synthesis thereof. The process comprises the double reductive amination reaction of a compound of formula (VI). 

Synthesis of an azasugar and intermediates thereof

The invention relates to a process for preparing a compound of formula (I) 

Method for preparing a farnesoid X receptor agonist

The present invention relates to a process for the preparation of an inhibitor of phosphodiesterase 4, in particular of phosphodiesterase 4B (PDE4B), and intermediates useful for its preparation.

Intermediates and process for the preparation of a crystalline form of a topical anti-inflammatory agent

The present invention relates to an improved synthesis and crystallization process of the 4-hydroxyphenylpyruvate dioxygenase (HPPD) inhibitor 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione, also known as nitisinone or NTBC.

Crystalline inhibitor of 4-hydroxyphenylpyruvate dioxygenase

The present invention relates to a process for the preparation of efinaconazole.

Process for the preparation of piperidine compounds

Crystalline inhibitor of 4-hydroxyphenylpyruvate dioxygenase, and a process of synthesis and crystallization thereof

Substantially stable to degradation Fesoterodine fumarate, a process for its preparation and a process for the synthesis of specific degradation impurities of Fesoterodine fumarate are disclosed.

Antimuscarinic compound having a low content of impurities

Process for the preparation of intermediates useful in the synthesis of miglustat and their use in its manufacture.

Synthesis of an azasugar and the intermediates thereof

The present invention relates to a process for the preparation of 1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine of formula (I), also known as vortioxetine, salts thereof, and intermediates useful for its synthesis.

Process for the preparation of an antidepressant and the intermediates thereof

Process for the preparation of an iminosugar, and the intermediates thereof, having known activity as a glycosyltransferase inhibitor and used, for example, in the treatment of Gaucher's disease.

Synthesis of a glycosyltransferase inhibitor

Process for the preparation of apixaban and intermediates useful for the preparation thereof.

Apixaban preparation process

The application discloses a process for the preparation of 5-deoxy-L-arabinose of formula (VI); comprising the conversion of a compound of formula (XII); wherein n is 0, 1 or 2; which can be used as intermediate for the synthesis of sapropterin. 

Process for the preparation of pteridine derivatives

Iminosugar, which possesses known activity as a glycosyltransferase inhibitor, and is used, for example, in the treatment of Gaucher's disease, in crystalline form, a process for its preparation and a pharmaceutical composition thereof.

Iminosugar in crystalline form

A process for the preparation of (R)-2-(3-diisopropylamino-1-phenylpropyl)-4-(hydroxymethyl)-phenol isobutyrate (Fesoterodine) or a pharmaceutically acceptable salt thereof having low content in impurities.

Process for the preparation of fesoterodine or a salt thereof

A process for the preparation of (R)-2-(3-diisopropylamino-1-phenylpropyl)-4-(hydroxymethyl)-phenol isobutyrate (Fesoterodine), its (S)-enantiomer, and novel intermediates useful in the synthesis.

Growing community of inventors

Baranzate, Italy

Emanuele Attolino